Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Ramucirumab
Related studies linked through entity extraction aliases.
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
AB122 Platform Study
- Status
- RECRUITING
- Phase
- PHASE1
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
- Status
- TERMINATED
- Phase
- PHASE3
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction
- Status
- COMPLETED
- Phase
- NA
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
- Status
- TERMINATED
- Phase
- PHASE2
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Status
- WITHDRAWN
- Phase
- PHASE2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- Status
- RECRUITING
- Phase
- PHASE2